LDH elevation

The GG (rs1801131-G/rs1801133-G) haplotype elevated LUAD risk by 1.53-fold (P = 0.022).ConclusionIn the Guangxi Zhuang cohort, the MTHFR rs1801131 GG genotype may represent a population-specific marker associated with LUAD susceptibility and poorer prognosis. Its combination with elevated LDH may provide supplementary information for risk stratification, although further validation in larger multicenter and multi-ethnic cohorts is required.

After a dose of ifosfamide/etoposide elsewhere, therapy was revised to ifosfamide, carboplatin, and etoposide plus brentuximab vedotin, with marked improvement by 2 cycles and cutaneous resolution by 5; she died of cardiopulmonary failure before the sixth cycle. This case underscores generous sampling, focused immunohistochemistry, and staging; negative ALK/EMA does not exclude systemic disease, and CD30-directed therapy can yield rapid cutaneous responses.

This review synthesizes the molecular mechanisms through which LDHA drives tumor progression, dissects its context-specific functions in CTC biology, and evaluates the translational potential of LDHA-targeted strategies, with a focused emphasis on oxamate, as a transformative anti-metastatic therapeutic paradigm. By filling a critical gap in synthesizing oxamate's distinct metabolic-immune regulatory actions, this work addresses an unmet need in the management of advanced, treatment-refractory cancers.

ASCT was associated with the most durable survival among consolidation strategies after R-MVP induction. These findings, derived from a large real-world, multi-institutional cohort, support ASCT as the preferred consolidation for eligible patients while underscoring the heterogeneity of current practice and the need for prospective validation.

The presence of DTCs in the BM is associated with the prognosis of AITL. Pleural effusion constitutes an independent adverse prognostic factor. Loss of CD7 correlates with shorter OS, and a profile combining CD3 expression, elevated LDH, and decreased HGB serves as a useful predictor of disease progression.

P2, N=30, Active, not recruiting, International Extranodal Lymphoma Study Group (IELSG) | Recruiting --> Active, not recruiting

P1/2, N=30, Recruiting, M.D. Anderson Cancer Center | Suspended --> Recruiting

P3, N=77, Active, not recruiting, Takeda | Recruiting --> Active, not recruiting

Therapeutic management followed an early, aggressive strategy, frequently utilizing cyclophosphamide (45.8%) and methotrexate (37.5%), with Janus kinase (JAK) inhibitors or rituximab employed in refractory cases. The observed dissociation between low CK/CRP and elevated LDH underscores the necessity for a high index of suspicion, with LDH serving as a superior marker for disease activity. While ILD presents a significant risk, early and intensive multi-modal intervention may yield superior survival outcomes in European patients compared to the historical mortality rates reported in Asian cohorts.

Functionally, co-culture assays showed that knockdown of CD70 in B-lymphoma cells reduced naive CD4+ and CD8+ T-cell subsets, whereas CD79BY197H transfected B-lymphoma cells enhanced tumor cell viability. Our findings comprehensively characterize FL/DLBCL and tFL molecularly, elucidating their distinct pathogenesis and rationalize CD70 and CD79B targeted immunotherapies.

PCBP2 suppresses MTUS1 expression via 3'UTR-mediated degradation, inhibiting pyroptosis and promoting ESCC progression, suggesting the PCBP2/MTUS1 axis as a potential therapeutic target to enhance chemotherapy efficacy.

An etoposide-containing CHOP variant (ECHOP/CHOEP, days 1-5) was initiated with parallel continuous renal replacement therapy (CVVHDF) to stabilize acid-base and electrolytes as a bridge to chemotherapy...A focused review of 18 recent case reports (2021-2025) suggests that timely, standardized antitumor therapy is frequently followed by a rapid, time-locked fall in lactate, whereas the absence of definitive oncologic treatment portends uniformly poor short-term outcomes. This case underscores that, in hemodynamically stable patients with refractory hyperlactatemia, early consideration of CWE and prompt tumor-directed therapy-supported by targeted organ support such as CRRT-offer the most reliable path to metabolic reversal and recovery.